The Six Databases Behind Every Public Company, and Why Nobody Reads All of Them

Introduction

Every public company in the United States leaves a paper trail across multiple government databases. These records are filed under legal obligation, not marketing objectives. They are not edited by PR teams. They are not timed for earnings calls. They simply exist, quietly accumulating in federal systems that anyone can access for free.

The problem is not access. The problem is that almost nobody looks at all of them together. An analyst might live inside SEC EDGAR but never check PACER. A pharma investor might follow ClinicalTrials.gov but skip USASpending.gov entirely. A retail investor reading press releases might not use any of them.

This article walks through all six databases, explains what each one actually contains, identifies which types of companies each database is most relevant for, and highlights the specific things you can find in these records that you will never find in a company's own communications.

1. SEC EDGAR

What It Contains

EDGAR (Electronic Data Gathering, Analysis, and Retrieval) stores every filing submitted to the SEC since 1993. This includes annual reports (10-K), quarterly reports (10-Q), current event disclosures (8-K), proxy statements (DEF 14A), insider trading reports (Forms 3, 4, and 5), registration statements for new securities (S-1), and hundreds of other form types.

The database also includes correspondence between companies and SEC staff. When the SEC reviews a filing and sends a comment letter asking for clarification, both the letter and the company's response are published on EDGAR. These exchanges are some of the most revealing documents in the entire system.

What You Will Find That Press Releases Do Not Tell You

• Risk factors that companies are legally required to disclose. The 10-K's risk factor section often runs 20 to 40 pages. Companies must list every material risk they are aware of, including pending litigation, regulatory investigations, customer concentration, and supply chain vulnerabilities. These risks rarely appear in investor presentations.
• Related-party transactions. Buried in the notes to financial statements, you will find details about deals between the company and its executives, board members, or their family members. A CEO leasing office space from a company he personally owns, for example, must be disclosed here.
• SEC comment letters. When the Division of Corporation Finance questions a company's accounting treatment, revenue recognition method, or disclosure language, the full back-and-forth is published. A company might describe a transaction as “strategic” in its press release while the SEC is asking pointed questions about whether the accounting complies with GAAP.
• Insider selling patterns. Forms 3, 4, and 5 track every purchase and sale of company stock by officers and directors. A pattern of heavy insider selling while the company publicly expresses optimism is a signal that no earnings call will reveal.
• Off-balance-sheet liabilities. Footnotes in the 10-K disclose operating lease obligations, purchase commitments, contingent liabilities, and variable interest entities that may not appear on the balance sheet at first glance.

Most Relevant For

Every public company. EDGAR is the baseline. If you are researching any US-listed stock, this is where you start. There is no substitute for reading the actual filings rather than relying on summaries written by third parties.

2. FINRA BrokerCheck

What It Contains

BrokerCheck provides detailed background reports on over 600,000 currently registered brokers and 3,500 brokerage firms. Each report includes employment history, licensing and exam information, regulatory actions, customer disputes, and criminal disclosures.

For firms, BrokerCheck shows the number of registered representatives, any regulatory events, arbitration cases, and whether the firm has been expelled or suspended by FINRA.

What You Will Find That Press Releases Do Not Tell You

• Executive disciplinary history. When a public company's CEO, CFO, or board member previously worked as a registered broker, their BrokerCheck record may include customer complaints, regulatory sanctions, or terminations for cause. Companies rarely volunteer this information in their proxy statements.
• Patterns of customer complaints. A brokerage firm facing a cluster of customer arbitration cases involving similar allegations (unauthorized trading, unsuitable recommendations, excessive fees) is a signal of systemic issues that will not appear in the firm's marketing materials.
• Firm association history. BrokerCheck shows which firms a broker has been associated with and why each association ended. A string of terminations followed by moves to smaller, less reputable firms is a meaningful pattern.
• Regulatory event details. FINRA enforcement actions include specific descriptions of the violations. A company may announce a settlement as “resolved” while the BrokerCheck record describes the underlying conduct in detail.

Most Relevant For

Financial services companies, brokerage firms, investment banks, fintech companies with broker-dealer subsidiaries, and any company whose leadership team includes former registered representatives. Also valuable when evaluating SPACs, since SPAC sponsors frequently come from financial services backgrounds.

3. USASpending.gov

What It Contains

USASpending.gov tracks over $6 trillion in annual federal spending. For investors, the most valuable data is the contracts database, which includes every federal contract awarded, the recipient company, the dollar amount, the awarding agency, the period of performance, and the type of work.

The system also tracks grants, direct payments, loans, insurance, and other forms of financial assistance. Data goes back to fiscal year 2008 and is updated daily.

What You Will Find That Press Releases Do Not Tell You

• Real government revenue concentration. A defense contractor might describe its business as “diversified” while USASpending reveals that 85% of its revenue comes from a single agency or program. Contract expiration dates show when that revenue is at risk.
• Contract modifications and de-scoping. The original contract award gets a press release. Subsequent modifications that reduce the scope or funding often do not. On USASpending, every modification is recorded, including reductions.
• Competitor contract wins. When a rival company wins the contract your company was competing for, that award appears on USASpending long before (or instead of) any public announcement.
• Small business set-aside status. Some companies receive contracts through small business programs. If a company is growing rapidly and approaching the size limit for its set-aside category, its ability to win future contracts through that channel may be at risk.
• Subcontractor relationships. While USASpending primarily tracks prime contracts, related databases like FPDS (Federal Procurement Data System) can reveal subcontracting relationships that show how companies are actually positioned in the supply chain.

Most Relevant For

Defense contractors (Lockheed Martin, Raytheon, L3Harris), government IT services companies (Booz Allen, Leidos, SAIC), healthcare companies with government contracts, construction and infrastructure firms, and any company that lists the US government as a significant customer in its 10-K.

4. USPTO

What It Contains

The USPTO database contains the full text and images of every US patent granted since 1790 and every patent application published since 2001. It also includes the complete registry of trademarks. For patents, the database shows the inventor, assignee (usually the company), filing date, grant date, patent claims, cited prior art, and the full specification.

The Patent Trial and Appeal Board (PTAB) records are also public. These include inter partes reviews (IPR) and post-grant reviews (PGR) where competitors challenge the validity of patents.

What You Will Find That Press Releases Do Not Tell You

• Whether a company's technology is actually novel. Patent claims define the exact scope of legal protection. A company might market a product as “proprietary” or “breakthrough” while its patent claims are narrow, heavily amended during prosecution, or built on expiring prior art.
• Patent challenges from competitors. When a competitor files an IPR challenge at PTAB, the company's patent might be invalidated or narrowed. These proceedings are publicly available but rarely make it into earnings calls unless the outcome is favorable.
• R&D direction. Patent applications are published 18 months after filing. This means you can see what a company was working on a year and a half ago, even if the company has not publicly announced the product or technology yet.
• Patent expiration timelines. For pharmaceutical and biotech companies, patent expiration dates are directly tied to revenue cliffs. Generic manufacturers can begin selling competing products once key patents expire.
• Inventor departures. By tracking the names of inventors on recent patent applications and comparing them to earlier filings, you can identify when key technical personnel have left the company. This is especially relevant for small-cap biotech and deep-tech companies.

Most Relevant For

Pharmaceutical and biotech companies (patent cliffs), semiconductor firms, technology hardware companies, medical device manufacturers, and any company that cites its patent portfolio as a competitive advantage in its 10-K. Also relevant for evaluating companies involved in patent infringement litigation.

5. PACER

What It Contains

PACER contains the dockets and documents for every case filed in US federal courts. This includes civil lawsuits, criminal cases, bankruptcy filings, and appeals. Each case docket shows every motion, brief, order, and ruling filed in the case, along with the parties involved and the judge assigned.

For investors, the most relevant categories are securities fraud class actions, patent infringement lawsuits, antitrust cases, regulatory enforcement actions, and bankruptcy proceedings.

What You Will Find That Press Releases Do Not Tell You

• Lawsuits the company has not disclosed. Companies are only required to disclose litigation they consider “material” in their SEC filings. A lawsuit that has not yet been deemed material might still appear on PACER. Some companies are defendants in dozens of cases that never make it into a 10-K.
• The actual allegations in detail. A press release might say the company “disagrees with the claims.” The complaint on PACER contains the specific allegations, the evidence cited, the damages sought, and the legal theories being advanced.
• Settlement terms. While many settlements are confidential, court orders approving settlements, fee awards, and distribution plans can reveal the actual cost. In securities class actions, the settlement amount is public.
• Bankruptcy details. When suppliers, customers, or competitors file for bankruptcy, their filings on PACER reveal creditor lists, asset valuations, and the extent of financial distress. A company's largest customer entering Chapter 11 is information you want before the accounts receivable write-down shows up in the next quarterly filing.
• Government investigations becoming cases. When the DOJ or SEC files an enforcement action, it appears on PACER. The complaint often reveals the scope and duration of the investigation, which may be far more extensive than the company's own disclosure suggested.

Most Relevant For

Companies facing securities fraud class actions, patent-heavy industries (pharma, tech), companies in regulated industries (banks, healthcare, energy), companies with large government contracts, and any company that lists “legal proceedings” as a material risk in its 10-K. Particularly important for small-cap and mid-cap companies where a single lawsuit can meaningfully affect the business.

6. ClinicalTrials.gov

What It Contains

ClinicalTrials.gov contains registration records for over 450,000 clinical studies in all 50 US states and over 220 countries. Each record includes the study title, sponsor, phase (1 through 4), enrollment target, start date, estimated completion date, primary and secondary endpoints, eligibility criteria, and, for completed studies, basic results.

Registration is a legal requirement. Under FDAAA 801, sponsors of clinical trials involving FDA-regulated drugs, biologics, and devices must register their studies and report results. This means the database captures trials that companies might otherwise keep quiet about, especially failed ones.

What You Will Find That Press Releases Do Not Tell You

• Trials that were terminated or withdrawn. A company might announce the start of a clinical trial with fanfare. If the trial is later terminated for futility, safety concerns, or business reasons, ClinicalTrials.gov records that status change. The press release announcing the termination may never come, or may come months later.
• Enrollment shortfalls and timeline slippage. The registry shows actual enrollment versus target enrollment, and estimated versus actual completion dates. A Phase 3 trial that targeted 500 patients and has enrolled 120 after two years is a red flag that earnings call guidance may not acknowledge.
• Endpoint changes. When a company modifies the primary or secondary endpoints of a trial after it has started, that amendment is recorded. Changing your success criteria mid-trial is a significant signal, and it rarely appears in company communications.
• Competitor pipeline activity. By searching for trials targeting the same condition or using the same mechanism of action, you can map the competitive landscape. A company claiming “first-in-class” status may have multiple competitors running similar trials.
• Results data before publication. Sponsors are required to post summary results within one year of completing a trial. These results sometimes appear on ClinicalTrials.gov before the peer-reviewed paper is published, giving you an early look at whether the trial met its endpoints.

Most Relevant For

Pharmaceutical companies, biotech companies (especially clinical-stage pre-revenue biotechs where the entire valuation depends on trial outcomes), medical device companies, CROs (contract research organizations like IQVIA and Charles River), and any company whose 10-K mentions an FDA approval pathway as a key business milestone.

Where the Databases Connect

These six databases are most powerful when cross-referenced. Here are examples of the connections that emerge when you read them in combination:

No single database gives you the full picture. The value is in the overlap. When the story a company tells in its press releases contradicts what its filings, court records, patents, and clinical trial data show, that gap is where the real risk lives.

Why This Matters

The information in these databases is not hidden. It is public, free (with the partial exception of PACER), and legally mandated. The barrier has never been access. It has been time. Reading a single 10-K takes hours. Checking PACER for pending litigation takes more time. Cross-referencing patent expiration dates with revenue forecasts takes more time still. Multiply that across all six databases and you understand why almost nobody does it.

That is exactly the gap that automated investigative tools are built to close. When a system can pull from SEC filings, court records, patent databases, clinical trial registries, and government contract records simultaneously, it can surface the contradictions and red flags that manual research would take days to find.

Whether you use an automated tool or do the work manually, the principle is the same: the most important information about a public company is almost never in the press release. It is in the databases that the company was required to file into by law. The six databases covered in this article are the starting point. They are free. They are public. And if you are making investment decisions without consulting them, you are working with an incomplete picture.